During the past decade, The Research Institute of the McGill University Health Centre (MUHC) conducted 83 clinical trials. In the 10-year time frame, 83 clinical trials started and 18 clinical trials were completed, i.e. on average, 21.7% percent of trials that started reached the finish line to date. In the past 5 years, 38 clinical trials started and 15 clinical trials were completed. i.e. 39.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Research Institute of the McGill University Health Centre (MUHC)" #1 sponsor was "McGill University Health Centre/Research Institute of the McGill University Health Centre" with 15 trials, followed by "Canadian Cancer Trials Group" with 14 trials sponsored, "NRG Oncology" with 14 trials sponsored, "National Cancer Institute (NCI)" with 12 trials sponsored and "Pfizer" with 12 trials sponsored. Other sponsors include 35 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Research Institute of the McGill University Health Centre (MUHC)" #1 collaborator was "National Cancer Institute (NCI)" with 24 trials as a collaborator, "NRG Oncology" with 9 trials as a collaborator, "Canadian Cancer Trials Group" with 5 trials as a collaborator, "AstraZeneca" with 4 trials as a collaborator and "Canadian Institutes of Health Research (CIHR)" with 3 trials as a collaborator. Other collaborators include 101 different institutions and companies that were collaborators in the rest 94 trials.

According to Clinical.Site data, the most researched conditions in "The Research Institute of the McGill University Health Centre (MUHC)" are "Invasive Breast Carcinoma" (3 trials), "Stage IIIA Breast Cancer" (3 trials), "Bladder Cancer" (2 trials), "Breast Adenocarcinoma" (2 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "The Research Institute of the McGill University Health Centre (MUHC)" in a lesser frequency.

Most popular intervention types in "The Research Institute of the McGill University Health Centre (MUHC)" are "Drug" (59 trials), "Other" (33 trials), "Radiation" (30 trials), "Biological" (14 trials) and "Procedure" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Quality-of-Life Assessment" (14 trials), "Laboratory Biomarker Analysis" (11 trials), "Cisplatin" (9 trials) and "Paclitaxel" (7 trials). Other intervention names were less common.

The vast majority of trials in "The Research Institute of the McGill University Health Centre (MUHC)" are 85 trials for "All" genders, 10 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "The Research Institute of the McGill University Health Centre (MUHC)". 1 are not yet recruiting, 30 are recruiting, 45 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in The Research Institute of the McGill University Health Centre (MUHC), 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in The Research Institute of the McGill University Health Centre (MUHC), 1 "Phase 1" clinical trials were conducted, 39 "Phase 2" clinical trials and 48 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 10 trials that are defined as “Not Applicable".